Studying Gene Expression in Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT ID: NCT01057303
Last Updated: 2015-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2010-02-28
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at gene expression in tissue samples from young patients with acute myeloid leukemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01229956
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia
NCT01057290
DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
NCT00899652
Biomarkers in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
NCT01298414
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421
NCT01035307
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Examine mRNA from pediatric patients with acute myeloid leukemia with 11q23 translocations by reverse transcriptase-PCR to quantify expression of EVI1 splice variants.
OUTLINE: Cryopreserved mRNA from diagnostic samples is analyzed for gene expression by reverse transcriptase-PCR.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RNA analysis
gene expression analysis
reverse transcriptase-polymerase chain reaction
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of pediatric acute myeloid leukemia with 11q23 abnormalities
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amy Heerema-McKenney, MD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AAML10B15
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000664144
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02205
Identifier Type: REGISTRY
Identifier Source: secondary_id
AAML10B15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.